

# Henry S Friedman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1238965/publications.pdf>

Version: 2024-02-01

136  
papers

7,730  
citations

101543

36  
h-index

53230

85  
g-index

139  
all docs

139  
docs citations

139  
times ranked

8545  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 4733-4740.	1.6	2,219
2	Recurrent Glioblastoma Treated with Recombinant Poliovirus. <i>New England Journal of Medicine</i> , 2018, 379, 150-161.	27.0	570
3	Frequent <i>ATR</i> , <i>CIC</i> , <i>FUBP1</i> and <i>IDH1</i> mutations refine the classification of malignant gliomas. <i>Oncotarget</i> , 2012, 3, 709-722.	1.8	532
4	Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. <i>Nature</i> , 2015, 519, 366-369.	27.8	429
5	Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 393-403.	2.3	331
6	Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. <i>Clinical Cancer Research</i> , 2017, 23, 1898-1909.	7.0	215
7	Ubiquitination-Dependent Proteolysis of O <sup>6</sup> -Methylguanine-DNA Methyltransferase in Human and Murine Tumor Cells following Inactivation with O <sup>6</sup> -Benzylguanine or 1,3-Bis(2-chloroethyl)-1-nitrosourea. <i>Biochemistry</i> , 1996, 35, 1328-1334.	2.5	203
8	Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. <i>Nature Genetics</i> , 2014, 46, 726-730.	21.4	148
9	Phase I studies of treatment of malignant gliomas and neoplastic meningitis with <sup>131</sup> I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab?) <sub>2</sub> -a preliminary report. <i>Journal of Neuro-Oncology</i> , 1995, 24, 109-122.	2.9	125
10	The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. <i>Nature Communications</i> , 2018, 9, 2087.	12.8	124
11	Prognostic implications of chromosome 17p deletions in human medulloblastomas. <i>Journal of Neuro-Oncology</i> , 1995, 24, 39-45.	2.9	123
12	Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: A pediatric oncology group study. <i>Annals of Neurology</i> , 1998, 44, 313-316.	5.3	113
13	Exercise Behavior, Functional Capacity, and Survival in Adults With Malignant Recurrent Glioma. <i>Journal of Clinical Oncology</i> , 2011, 29, 2918-2923.	1.6	107
14	Treatment of infants with malignant gliomas: The Pediatric Oncology Group Experience. <i>Journal of Neuro-Oncology</i> , 1996, 28, 245-56.	2.9	91
15	Long term survivors of childhood brain stem gliomas treated with hyperfractionated radiotherapy: Clinical characteristics and treatment related toxicities. <i>Cancer</i> , 1996, 77, 555-562.	4.1	90
16	Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. <i>Cancer Research</i> , 2018, 78, 256-264.	0.9	82
17	Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 34, 171-174.	2.3	78
18	Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. <i>Nature Communications</i> , 2021, 12, 352.	12.8	77

#	ARTICLE	IF	CITATIONS
19	O6-benzylguanine-mediated enhancement of chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 943-8.	4.1	67
20	Topotecan treatment of adults with primary malignant glioma. <i>Cancer</i> , 1999, 85, 1160-1165.	4.1	65
21	Lack of efficacy of postoperative chemotherapy and delayed radiation in very young children with pineoblastoma. <i>Medical and Pediatric Oncology</i> , 1995, 25, 38-44.	1.0	63
22	Medulloblastoma: tumor biological and clinical perspectives. <i>Journal of Neuro-Oncology</i> , 1991, 11, 1-15.	2.9	59
23	Preradiation chemotherapy in advanced medulloblastoma a pediatric oncology group pilot study. <i>Cancer</i> , 1993, 72, 2755-2762.	4.1	58
24	Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 41, 485-490.	2.3	57
25	Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. , 1996, 26, 105-110.		56
26	Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. <i>Journal of Neuro-Oncology</i> , 2009, 95, 393-400.	2.9	53
27	Chemotherapy for pilocytic astrocytomas. <i>Cancer</i> , 1993, 71, 3165-3172.	4.1	50
28	Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2018, 137, 349-356.	2.9	49
29	Modulation of cyclophosphamide activity by O <sup>6</sup> -alkylguanine-DNA alkyltransferase. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 80-85.	2.3	47
30	Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. <i>Journal of Neuro-Oncology</i> , 2009, 95, 129-134.	2.9	47
31	Successful treatment of childhood pilocytic astrocytomas metastatic to the leptomeninges with high-dose Cyclophosphamide. <i>Medical and Pediatric Oncology</i> , 1996, 27, 32-39.	1.0	45
32	Is there a correlation between duration of presenting symptoms and stage of medulloblastoma at the time of diagnosis?. , 1996, 78, 874-880.		45
33	Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma. <i>Oncologist</i> , 2018, 23, 157-e21.	3.7	44
34	Selection of a management strategy for pediatric brainstem tumors. <i>Medical and Pediatric Oncology</i> , 1989, 17, 116-125.	1.0	43
35	Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study. <i>Journal of Neuro-Oncology</i> , 1999, 43, 43-47.	2.9	42
36	Microsatellite analysis of childhood brain tumors. , 1996, 15, 54-63.		40

#	ARTICLE	IF	CITATIONS
37	Comparison of serial PET and MRI scans in a pediatric patient with a brainstem glioma. <i>Medical and Pediatric Oncology</i> , 1993, 21, 301-306.	1.0	37
38	The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. <i>Cancer</i> , 2003, 97, 2359-2362.	4.1	37
39	Reversal of radiation-induced neutropenia by granulocyte colony-stimulating factor. <i>Medical and Pediatric Oncology</i> , 1992, 20, 240-242.	1.0	36
40	Long term response in a patient with neoplastic meningitis secondary to melanoma treated with <sup>131</sup> I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab?) <sub>2</sub> . <i>Cancer</i> , 2001, 91, 1809-1813.	4.1	35
41	Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities. <i>Cancer Research</i> , 2018, 78, 36-50.	0.9	35
42	Criteria and definitions for response and relapse in children with brain tumors. <i>Cancer</i> , 1985, 56, 1824-1826.	4.1	34
43	Childhood hepatic mesenchymoma: Successful treatment with surgery and multiple-agent chemotherapy. <i>Medical and Pediatric Oncology</i> , 1988, 16, 62-65.	1.0	34
44	Modulation of Melphalan Resistance in Glioma Cells with a Peripheral Benzodiazepine Receptor Ligand <sup>α</sup> -Melphalan Conjugate. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 1726-1730.	6.4	32
45	Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma. <i>Oncologist</i> , 2015, 20, 727-728.	3.7	32
46	Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 345-349.	2.3	31
47	Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 393-403.	2.3	31
48	MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation. <i>Cancer Research</i> , 2019, 79, 3383-3394.	0.9	30
49	Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma. <i>Medical and Pediatric Oncology</i> , 1995, 25, 190-196.	1.0	29
50	A phase II study of every other day high-dose ifosfamide in pediatric brain tumors. <i>Journal of Neuro-Oncology</i> , 1995, 25, 77-84.	2.9	27
51	Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma. <i>Oncologist</i> , 2018, 23, 889-e98.	3.7	26
52	Adjunctive perampanel for glioma-associated epilepsy. <i>Epilepsy &amp; Behavior Case Reports</i> , 2018, 10, 114-117.	1.5	26
53	A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POC 9631): A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26373.	1.5	25
54	Treatment of patients with pineoblastoma with high dose cyclophosphamide. , 1996, 26, 387-392.		23

#	ARTICLE	IF	CITATIONS
55	Treatment of adults with progressive oligodendroglioma with carboplatin (CBDCA): Preliminary results. , 1998, 31, 16-18.		22
56	Osteoblastic metastases from astrocytomas: A report of two cases. Medical and Pediatric Oncology, 1991, 19, 318-324.	1.0	20
57	Severe Adverse Immunologic Reaction in a Patient with Glioblastoma Receiving Autologous Dendritic Cell Vaccines Combined with GM-CSF and Dose-Intensified Temozolomide. Cancer Immunology Research, 2015, 3, 320-325.	3.4	20
58	The Localisation of Radiolabeled Murine Monoclonal Antibody 81C6 and its Fab Fragment in Human Glioma Xenografts in Athymic Mice. British Journal of Neurosurgery, 1988, 2, 179-191.	0.8	19
59	Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. Journal of Neuro-Oncology, 1999, 44, 233-241.	2.9	18
60	O 6 -Benzylguanidine-mediated enhancement of nitrosourea activity in Mer âˆ’ central nervous system tumor xenografts - implications for clinical trials. Cancer Chemotherapy and Pharmacology, 2000, 45, 437-440.	2.3	18
61	A cross sectional analysis from a single institutionâ€™s experience of psychosocial distress and health-related quality of life in the primary brain tumor population. Journal of Neuro-Oncology, 2017, 134, 363-369.	2.9	18
62	Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors. Cancer Chemotherapy and Pharmacology, 1998, 42, 479-482.	2.3	17
63	Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR). Cancer Chemotherapy and Pharmacology, 1999, 43, 73-79.	2.3	17
64	Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.. Journal of Clinical Oncology, 2016, 34, 2061-2061.	1.6	17
65	Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines. Journal of Neuro-Oncology, 1995, 25, 9-17.	2.9	16
66	Papillary adenocarcinoma of the renal pelvis in a child: Case report and brief review of the literature. Medical and Pediatric Oncology, 1990, 18, 81-86.	1.0	15
67	Biodistribution of O 6-benzylguanidine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL. Cancer Chemotherapy and Pharmacology, 1994, 35, 121-126.	2.3	15
68	Safety and efficacy of the addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma multiforme.. Journal of Clinical Oncology, 2012, 30, 2094-2094.	1.6	15
69	Activity of high-dose cyclophosphamide in the treatment of childhood malignant gliomas. , 1998, 30, 75-80.		14
70	Activity of ifofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice. Cancer Chemotherapy and Pharmacology, 2001, 48, 413-416.	2.3	14
71	Propionibacterium shunt nephritis in two adolescents with medulloblastoma. Cancer, 1983, 52, 330-333.	4.1	13
72	Cerebral atrophy in an infant following treatment with ifosfamide. Medical and Pediatric Oncology, 1994, 23, 380-383.	1.0	13

#	ARTICLE	IF	CITATIONS
73	Carboplatin pharmacokinetics in young children with brain tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 38, 395-400.	2.3	13
74	Familial erythrophagocytic lymphohistiocytosis: Late relapse despite continuous high-dose VP-16 chemotherapy. <i>Medical and Pediatric Oncology</i> , 1990, 18, 27-29.	1.0	12
75	Cyclophosphamide therapy of medulloblastoma: From the laboratory to the clinic and back again (and again and again). <i>Journal of Neuro-Oncology</i> , 1995, 24, 103-108.	2.9	12
76	Second primary cancers in long-term survivors of glioblastoma. <i>Neuro-Oncology Practice</i> , 2019, 6, 386-391.	1.6	12
77	Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 15-21.	2.3	11
78	Evaluation of pre-radiotherapy cyclophosphamide in patients with newly diagnosed glioblastoma multiforme. Writing Committee for The Brain Tumor Center at Duke. <i>Journal of Neuro-Oncology</i> , 2000, 46, 151-156.	2.9	11
79	Fabrication and testing of a device capable of reducing the incidence of ventricular shunt promoted metastasis. <i>Journal of Neuro-Oncology</i> , 1996, 27, 39-46.	2.9	10
80	Single-center retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice. <i>Health Science Reports</i> , 2019, 2, e114.	1.5	10
81	Treatment of lymphohistiocytic erythrophagocytosis with VP-16 and aziridinybenzoquinone. <i>Medical and Pediatric Oncology</i> , 1987, 15, 58-61.	1.0	9
82	Transient Late Magnetic Resonance Imaging Changes Suggesting Progression of Brain Stem Glioma: Implications for Entry Criteria for Phase II Trials. <i>Neurosurgery</i> , 1988, 23, 248-253.	1.1	9
83	Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. <i>Supportive Care in Cancer</i> , 2020, 28, 2229-2238.	2.2	9
84	Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2068-2068.	1.6	9
85	Severe Mycoplasma Pneumonia in Three Sisters with Sickle Cell Disease. <i>Pediatric Hematology and Oncology</i> , 1986, 3, 259-265.	0.8	8
86	Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 27, 278-284.	2.3	8
87	False positive images in the follow-up of patients with brain tumors. , 1997, 28, 127-131.		8
88	MGMT: Immunohistochemical Detection in High-Grade Astrocytomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 57-64.	1.7	8
89	Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13526-e13526.	1.6	8
90	False-positive MRI detection of recurrent or metastatic pediatric infratentorial tumors. <i>Medical and Pediatric Oncology</i> , 1993, 21, 350-355.	1.0	6

#	ARTICLE	IF	CITATIONS
91	Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 40, 409-414.	2.3	6
92	A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 33-40.	2.0	6
93	Cellular Mechanisms of Cyclophosphamide Resistance: Model Studies in Human Medulloblastoma Cell Lines. <i>Cancer Treatment and Research</i> , 2002, 112, 199-209.	0.5	6
94	Phase I trial of combination of antitumor immunotherapy targeted against <i>cytomegalovirus</i> (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM).. <i>Journal of Clinical Oncology</i> , 2016, 34, e13518-e13518.	1.6	6
95	Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. <i>Journal of Neuro-Oncology</i> , 2018, 138, 489-498.	2.9	5
96	Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population. <i>Complementary Therapies in Clinical Practice</i> , 2019, 36, 43-48.	1.7	5
97	Spiritual well-being and its association with health-related quality of life in primary brain tumor patients. <i>Neuro-Oncology Practice</i> , 2021, 8, 299-309.	1.6	5
98	LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS2065-TPS2065.	1.6	5
99	A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2022, 40, e14015-e14015.	1.6	5
100	Reproducibility of outcomes in sequential trials using CMV-targeted dendritic cell vaccination for glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2005-2005.	1.6	5
101	Performance of a nomogram for IDH-wild-type glioblastoma patient survival in an elderly cohort. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz036.	0.7	4
102	Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series. <i>Journal of Neuro-Oncology</i> , 2020, 147, 477-483.	2.9	4
103	Long term survivors of childhood brain stem gliomas treated with hyperfractionated radiotherapy: Clinical characteristics and treatment related toxicities. <i>Cancer</i> , 1996, 77, 555-562.	4.1	4
104	Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2034-2034.	1.6	4
105	Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2094-2094.	1.6	4
106	Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2020, 38, 2566-2566.	1.6	4
107	Bacterial Endocarditis in a Child with a Broviac Catheter. <i>Pediatric Hematology and Oncology</i> , 1987, 4, 131-136.	0.8	3
108	The effect ofl-amino acid oxidase on activity of melphalan against an intracranial xenograft. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 379-384.	2.3	3

#	ARTICLE	IF	CITATIONS
109	Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis. <i>CNS Oncology</i> , 2021, 10, CNS77.	3.0	3
110	Microsatellite analysis of childhood brain tumors. <i>Genes Chromosomes and Cancer</i> , 1996, 15, 54-63.	2.8	3
111	Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial. <i>Supportive Care in Cancer</i> , 2022, 30, 3463-3471.	2.2	3
112	HGG-22. PHASE 1b STUDY POLIO VACCINE SABIN-RHINOVIRUS POLIOVIRUS (PVSRIPO) FOR RECURRENT MALIGNANT GLIOMA IN CHILDREN. <i>Neuro-Oncology</i> , 2018, 20, i93-i93.	1.2	2
113	Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab (BEV) in subjects with recurrent malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2012, 30, 2074-2074.	1.6	2
114	Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2060-2060.	1.6	2
115	Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2027-2027.	1.6	1
116	Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT.. <i>Journal of Clinical Oncology</i> , 2013, 31, e13015-e13015.	1.6	1
117	Phase I study of the intratumoral administration of an oncolytic polio/rhinovirus recombinant (PVSRIPO) in recurrent glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS2106-TPS2106.	1.6	1
118	The addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM).. <i>Journal of Clinical Oncology</i> , 2012, 30, 2090-2090.	1.6	1
119	Long-term survivorship in adult primary glioblastoma: Clinical and neurological outcomes of a large, single-center study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9519-9519.	1.6	1
120	Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9553-9553.	1.6	1
121	Baseline cognitive function to predict survival in patients with glioblastoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10125-10125.	1.6	1
122	Introduction: Irinotecan in brain tumors. <i>Cancer</i> , 2003, 97, 2351-2351.	4.1	0
123	CNS Oncology: reflecting a rapidly changing landscape. <i>CNS Oncology</i> , 2012, 1, 1-2.	3.0	0
124	QOL-21DIET AND HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN THE PRIMARY BRAIN TUMOR POPULATION. <i>Neuro-Oncology</i> , 2015, 17, v192.3-v192.	1.2	0
125	Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 631618.	2.8	0
126	Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2095-2095.	1.6	0



#	ARTICLE	IF	CITATIONS
127	Analysis of high-dose methotrexate with rituximab versus other treatment regimens for primary central nervous system (CNS) lymphoma.. Journal of Clinical Oncology, 2013, 31, 2090-2090.	1.6	0
128	Single-institution retrospective review of newly diagnosed glioblastoma (GBM) patients (pts) treated on bevacizumab (BEV) in clinical practice.. Journal of Clinical Oncology, 2014, 32, 2082-2082.	1.6	0
129	Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM).. Journal of Clinical Oncology, 2014, 32, 3069-3069.	1.6	0
130	Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.. Journal of Clinical Oncology, 2015, 33, 2067-2067.	1.6	0
131	Phase 1 clinical trial of carboxyamidotriazole orotate (CTO) in combination with lomustine (CCNU) for adult patients with recurrent malignant glioma (MG).. Journal of Clinical Oncology, 2015, 33, e13004-e13004.	1.6	0
132	Secondary cancers in long-term survivors of primary glioblastoma.. Journal of Clinical Oncology, 2015, 33, e20616-e20616.	1.6	0
133	Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).. Journal of Clinical Oncology, 2015, 33, e13030-e13030.	1.6	0
134	Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).. Journal of Clinical Oncology, 2017, 35, e13533-e13533.	1.6	0
135	Reductions in exercise behavior and tumor progression in newly diagnosed glioblastoma (GBM) patients.. Journal of Clinical Oncology, 2017, 35, e21636-e21636.	1.6	0
136	A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma.. Journal of Clinical Oncology, 2022, 40, TPS2076-TPS2076.	1.6	0